Basic Information
ID: ALA5239758
Type: Binding
Description: Antagonist activity at human PXR in human HepG2 cells co-expressing luciferase gene under control of CYP3A4 promoter assessed as inhibition in rifampicin-induced receptor activation at 10 uM incubated for 24 hrs by luminescence based analysis relative to control
Organism: Homo sapiens
Cell type: HepG2
Activity Charts
Bioactivity
Activity Types for Assay ALA5239758
Inhibition
Compound Summary
| Parent Molecular Weight | ALogP | Polar Surface Area |
|---|---|---|
| 438.53 | 4.54 | 4.54 |
| 410.47 | 3.85 | 3.85 |
| 466.58 | 5.32 | 5.32 |
| 520.55 | 6.21 | 6.21 |
| 537.66 | 4.24 | 4.24 |
| 509.61 | 5.49 | 5.49 |
| 536.68 | 3.77 | 3.77 |
| 481.60 | 4.08 | 4.08 |
| 523.63 | 3.85 | 3.85 |
| 471.00 | 5.97 | 5.97 |
| 504.55 | 6.33 | 6.33 |
| 454.55 | 5.45 | 5.45 |
| 419.49 | 4.01 | 4.01 |
| 424.50 | 4.15 | 4.15 |
| 394.48 | 4.14 | 4.14 |
| 423.52 | 4.18 | 4.18 |
| 465.60 | 5.35 | 5.35 |
| 410.47 | 3.85 | 3.85 |
| 464.61 | 6.01 | 6.01 |
| 450.58 | 5.62 | 5.62 |
| 482.58 | 4.29 | 4.29 |
| 466.58 | 5.32 | 5.32 |
| 450.58 | 5.44 | 5.44 |
| 407.47 | 3.45 | 3.45 |
| 466.58 | 5.32 | 5.32 |
| 437.54 | 4.21 | 4.21 |
| 485.03 | 6.35 | 6.35 |
| 464.61 | 6.01 | 6.01 |
| 394.48 | 4.14 | 4.14 |
| 494.64 | 6.10 | 6.10 |
| 473.37 | 4.91 | 4.91 |
| 465.60 | 5.35 | 5.35 |
| 423.52 | 4.18 | 4.18 |
| 520.44 | ||
| 424.50 | 4.15 | 4.15 |
| 436.56 | 5.31 | 5.31 |
| 394.48 | 4.14 | 4.14 |
| 464.61 | 6.01 | 6.01 |
| 480.61 | 5.57 | 5.57 |
| 470.57 | 5.81 | 5.81 |
| 480.61 | 5.71 | 5.71 |
| 485.03 | 6.35 | 6.35 |
| 495.62 | 4.47 | 4.47 |
| 480.61 | 5.71 | 5.71 |
| 437.54 | 4.71 | 4.71 |
| 480.61 | 5.71 | 5.71 |
| 424.50 | 4.15 | 4.15 |
| 380.45 | 3.97 | 3.97 |
| 466.58 | 5.32 | 5.32 |
| 522.69 | 6.88 | 6.88 |
| 437.54 | 4.21 | 4.21 |
| 480.61 | 5.57 | 5.57 |
| 409.49 | 3.72 | 3.72 |
| 480.61 | 5.71 | 5.71 |
| 521.71 | 6.55 | 6.55 |
| 449.51 | 4.05 | 4.05 |
| 485.03 | 6.35 | 6.35 |
| 515.45 | 6.08 | 6.08 |
| 452.56 | 4.93 | 4.93 |
| 430.53 | 3.69 | 3.69 |